Warning letter
Provident Pharmaceuticals LLC [ARCHIVED]: warning letter of Nov 9, 2009
FDA warning letter 77225 · Denver District Office
Key facts
| Reference number | 77225 |
|---|---|
| Company | Provident Pharmaceuticals LLC [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Misbranded/Adulterated |
| Issue date | Nov 9, 2009 |
| Posted date | Nov 9, 2009 |
| Issuing office | Denver District Office |
| Product type | Drugs |
| CFR sections cited | 211.180(e), 201.115, 211.192, 211.22(d), 211.166(a), 210, 211.165(e) |
| Inspection city | Colorado Springs |
| Inspection ZIP | 80919 |
| Inspection start date | Jun 1, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: